The impact of metformin on myocardial hypertrophy: an updated systematic review, meta-analysis, and meta-regression of randomized controlled trials
Our data demonstrated that metformin administration results in a modest but significant effect in reducing LVMI, particularly over longer treatment durations and in non-diabetic individuals. However, its impact on other echocardiographic parameters remains uncertain. Despite the need for further research (experimental and clinical), our study supports metformin as a therapeutic strategy for optimizing cardiovascular benefits in diabetic and non-diabetic patients at risk of cardiac hypertrophy.
Authors
- Yasaman Mohammadi (ORCID: https://orcid.org/0000-0002-8013-0248)
- Alireza Azarboo (ORCID: https://orcid.org/0000-0003-3399-2360)
- Amirmohammad Khalaji (ORCID: https://orcid.org/0000-0002-6138-1914)
- Alessandro Cannavò (ORCID: https://orcid.org/0000-0001-8948-5961)
- Farhad Shaker (ORCID: https://orcid.org/0009-0003-5987-9873)
- Sayeh Jalali (ORCID: https://orcid.org/0009-0009-2757-4104)
- Ramin Assempoor
- Amin Javidan (ORCID: https://orcid.org/0009-0004-3425-0515)
- Omid Bahrami (ORCID: https://orcid.org/0009-0005-4310-711X)
- Niyousha Farahmandniya
Institutions
- Tehran University of Medical Sciences (IR)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1186/s13098-025-02047-2
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00